---

Education:

• B.S. 1975 Biochemistry University of California-Los Angeles
• M.S. 1976 Chemistry University of Washington
• B.S. Pharm. 1979 Pharmacy University of Washington
• Pharm.D. 1981 University of Tennessee

Overview

Paul, whose baccalaureate and master's degrees are in biochemistry and chemistry respectively, completed an oncology/pharmacokinetics fellowship at St. Jude Children's Research Hospital in Memphis. He was a faculty member at the University of Illinois for five years before moving to Madison in 1988. He now practices pharmacy in the oncology/hematology division at UW Hospital and Clinics and is an Associate Member of the UW Comprehensive Cancer Center. His two course offerings at the School of Pharmacy are Clinical Pharmacokinetics and Dietary Supplements.

Prof. Hutson's present research is in the areas of palliative care, and separately in population pharmacokinetic modeling. Current active or pending palliative care protocols include the treatment or prevention of chemotherapy-induced palmar-plantar erythrodysesthesia and peripheral neuropathy.

Dr. Hutson also contributes population pharmacokinetic modeling services using NONMEM and ADAPT to the Experimental Therapeutics Program of the UWCCC, as well as to other investigators in the Schools of Medicine and Veterinary Medicine. Current collaborative activities in pharmacokinetic modeling include sparse sampling in murine research cohorts, porcine retinoid deprivation/supplementation, and animal models of fluoroquinolone pharmacokinetics.

Work-Related Interests/Research:

Population Pharmacokinetic / Pharmacodynamic Modeling

Cancer-related Palliative Care:

Therapeutic Opiate Use / Global Regulatory Barriers

Palmar-plantar erythrodysesthesia

Chemotherapy-induced neuropathy

Highlighted Publications:

• Tremont-Lukats IW, Hutson PR, Backonja MM. A randomized, double-masked, placebo-controlled pilot trial of extended IV lidocaine infusion for relief of ongoing neuropathic pain. Clin J Pain. 2006;22 :266-71.
• Hutson PR, Love RR, Havighurst TC, Rogers E, Cleary JF., Effect of Exemestane on Tamoxifen Pharmacokinetics in Postmenopausal Women Treated for Breast Cancer. Accepted for publication, Clin Cancer Res 2005; 11: 8722-7.
• Love RR, Hutson PR, Havighurst TC, and Cleary JF. Endocrine effects of tamoxifen plus exemestane in postmenopausal women with breast cancer. Clinical Cancer Research 2005;11: 1500-3.
• Dubey S, Hutson P, Alberti D, Arzoomanian R, Binger K, Volkman J, Feierabend C, Wilding G, Schiller JH. Phase I study of docetaxel and topotecan in patients with advanced malignancies. J Oncol Pharm Pract. 2005;11:131-8.
• Forouzannia A, Schiller J, Berlin J, et al. A phase I study of Topotecan, as a radiosensitizer, for thoracic malignancies. Lung Cancer 2004;44:111-9.
• Mould DR, Holford NH, Schellens JH, Beijnen JH, Hutson PR, Rosing H, ten Bokkel Huinink WW, Rowinsky EK, Schiller JH, Russo M, Ross G. Population pharmacokinetic and adverse event analysis of topotecan in patients with solid tumors. Clin Pharmacol Ther. 2002;7:334-48.
• Cleary J, Gordon DB, Hutson P, Ward S. Incidence and characteristics of naloxone administration in medical oncology patients with cancer pain. J Pharmaceutical Care Pain Symptom Control 2000; 8(2): 65-73.
• Hutson PR, Tutsch KD, Rago R, Arzoomanian R, Alberti D, Pomplun M, Church D, Marnocha R, Cheng AL, Kehrli N, Wilding. G. Renal clearance, tissue distribution, and CA-125 responses in a Phase I trial of suramin. Clin Ca Res 1998; 4(6) 1429-1436.
• Schiller JH, Kim KM, Hutson PR, DeVore R, Glick J, Stewart J, Johnson D. Phase II study of topotecan in patients with extensive-stage small cell carcinoma of the lung: An Eastern Cooperative Oncology Group Trial (E1592). J Clin Oncol 1996: 14: 2345-2352.